Here are the 424B prospectus supplements from Myriad Genetics Inc (MYGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
Myriad Genetics, Inc. registered a shelf to offer up to $200,000,000 of common stock, preferred stock, depositary shares, debt securities and/or warrants under a prospectus dated March 4, 2026.
The prospectus describes the types of securities that may be sold from time to time and states that specific terms, pricing and net proceeds for any issuance will be provided in an accompanying prospectus supplement. Common stock outstanding totaled 93,508,165 shares as of February 19, 2026.